Tuesday, 9 December 2014
FDA approves blinatumomab to treat a rare form of acute lymphoblastic leukaemia
The USA Food and Drug Administration (FDA) approved on 3 December, 2014 blinatumomab (Blincyto) to treat patients with Philadelphia chromosome-negative precursor B-cell acute lymphoblastic leukaemia (B-cell ALL), an uncommon form of ALL. Read more here.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment